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Abstract
As a Cell and Molecular major with a Pre-Pharmacy emphasis, medicine has been an interest of
mine. The major cause of increasing bacterial resistance to beta-lactam antibiotics is due to the
expression of the enzyme beta-lactamase in bacteria. This leads to the inactivation of the
antibiotics and preventing cell death. The currently known inhibitors of beta-lactamase are
clavulanic acid, sulbactam, and tazobactam. These are the only inhibitors that have reached
clinical importance. Phthalic acids derivatives have been identified as potential inhibitors.
Phthalic acid, Terephthalic acid, and 1,2-Phenylenediacetic acid were tested for beta-lactamase
inhibition at various concentrations to determine the IC50 values. The data showed that
terephthalic acid was the most inhibitory of beta-lactamase. The IC50 for terephthalic acid was
not fully determined, however the smallest concentration of terephthalic acid tested,1.5 mM,
yielded a beta-lactamase activity of 34%, in other words an 66% inhibition. The IC50 values for
phthalic acid and 1,2-Phenylenediacetic acid were 8.0 +/- 0.6 mM and 2.8 +/- 0.8 mM,
respectively. Phthalic acid and 1,2-Phenylenediacetic acid are both similar in structure and
inhibition of beta lactamase. Terephthalic is the most different with its carboxyl groups spread
out the furthest. This could point towards the distance of the carboxyl groups having a greater
impact on inhibition of beta-lactamase. Although all three phthalic acid derivatives showed the
ability to inhibit b-lactamase, it is unlikely that these molecules would make it to the clinical level
due to the high concentration of each molecule needed to inhibit beta-lactamase activity.
Clinical drugs used are in the concentration of nanomolar while this experiment showed that
millimolar concentrations were necessary for inhibition. In the future, I hope another student
continues this research and takes a further look into the effect of the distance of the carboxyl
group has on the inhibition of beta-lactamase activity.

Introduction
Beta-lactam antibiotics work by blocking cell wall synthesis of the bacteria and are a
common drug used to treat bacterial infections. A major problem developing today in the world
is the increase in bacteria being resistant to beta-lactam antibiotics. (1,4) The major cause of
increasing bacterial resistance to beta-lactam antibiotics is due to the expression of the enzyme
beta-lactamase in bacteria (1,4). Beta-lactamase is able to hydrolyzes beta-lactam antibiotics in
bacteria that contain the beta-lactamase coding gene(1). This leads to the inactivating of the
antibiotics and preventing cell death. This problem has provided a challenge in finding betalactamase inhibitors so these beta-lactam antibiotics can continue to kill bacterial infections.
There are a few inhibitors that have been found already for beta-lactamase. The
currently know inhibitors are clavulanic acid, sulbactam, and tazobactam(2). Each of these are
the only three inhibitors that have reached clinical importance(2). However, some other potential
inhibitors of beta-lactamase have been identified, including phthalic acid derivatives.
A research study performed by Yukiko Hiraiwa, Akihiro Morinaka, Takayoshi Fukushima,
and Toshiaki Kudo has given evidence to this. In their study, they set out to find Metallo-blactamase inhibitory activity of phthalic acid derivatives and found that the two carboxyl groups
of phthalic acid derivative compounds might interact with zinc in the active site of IMP-1, which

could then inhibit the beta-lactamase produced. They then fixed the two carboxyl groups and
investigated the effect of substitution of the phenyl ring on metallo-beta-lactamase inhibitory
activity.(3) In the experiment 4-butyl-3-methylphthalic acid was recognized as a metallo-betalactamase inhibitor. The structure–activity relationship study of substituted phthalic acids
afforded 3-phenylphthalic acid derivatives as potent metallo-beta-lactamase inhibitors.(3)

Figure 1: Clavulanic acid

Inhibition of beta-lactamase by clavulanate. Trapped intermediates in cryo crystallographic
studies. [5,6,7]

The docking simulation of Terephthalic acid at the active site of beta-lactamase (1BLC). The
calculated KI was 2.1 mM [8].

The docking simulation of phthalic acid at the active site of beta-lactamase (1BLC). The
calculated KI was 2.2 mM [8]

The docking simulation of 1,2-Phenylenediacetic acid at the active site of beta-lactamase
(1BLC). The calculated KI was 1.4 mM. [8]

My proposal is to use the beta-Lactamase enzyme activity to find the beta-lactamase inhibiting
ability for phthalic acid, 1,2-phenylenediacetic acid, and terephthalic acid.
Beta-lactamase enzyme activity was assayed colorimetrically at 490 nm using the Sigma Aldrich
Beta-Lactamase Screening Kit (MAK222). The activity was measured by monitoring a colored
product by hydrolyzing the lactam ring of a substrate, nitrocefin. The structure of nitrocefin
shown below.

Figure 2: Phthalic Acid

Figure 3: 1,2-Phenylenediacetic Acid

Figure 4: Terephthalic Acid

Materials and Methods
Phthalic acid, terephthalic acid, 1,2-phenylenediacetic acid, the Beta-Lactamase Screening Kit (
MAK222) including beta-lactamase, beta-lactamase assay buffer and clavulanic acid, and
nitrocefin were purchased from Sigma Aldrich. Concentrations of 500mM of Phthalic acid,
terephthalic acid, and 1,2-phenylenediacetic acid were made using the the drugs and DMSO.
From the 500mM concentration, concentrations of 1.5mM, 2.5mM, 5mM, 25mM, and 50mM
were made for each drug. 30ul of enzymatic reaction mix consisting of 29uL b-Lactamase Assay
Buffer and 1uL Nitrocefin was added to 20 uL of each drug. The drug mixtures were then
incubated at 25 °C for 10 minutes. A blank sample without inhibitor was ran to establish a 100%
activity level. Clavulanic acid was also used as a known inhibitor of beta-lactamase activity to
have a control to compare results to. 30 uL enzyme was added to initiate the reaction. The
absorbance at 490nm was measured using a SpectraMax M5 microplate reader from Molecular
Devices in kinetic mode for 10 minutes, taking the absorbance reading every 30 seconds. The
data was then used to see beta-lactamase activity over time for each concentration to establish
an activity curve.
1.
Using phthalic acid and DMSO, make a 500mM concentration in order to make
additional concentration strengths to be tested. Add 249.21mg of phthalic acid with 3mL of
DMSO.
2.
Make concentrations from the 500mM concentration of 1.5mM, 2.5mM, 5mM, 25mM
50mM
3.
To make 1.5mM solution, add 3ul of the 500mM stock solution, 750ul of beta lactamase assay
buffer, and 247ul DMSO. Pipet 20ul into the first two wells of row A in the microplate.
4.
To make 2.5mM solution, add 5ul of the 500mM stock solution, 750ul of beta lactamase assay
buffer, and 245ul DMSO. Pipet 20ul into the first two wells of row B in the microplate.
5.
To make 5mM solution, add 10ul of the 500mM stock solution, 750ul of beta lactamase assay
buffer, and 240ul DMSO. Pipet 20ul into the first two wells of row C in the microplate.
6.
To make 15mM solution, add 30ul of the 500mM stock solution, 750ul of beta lactamase assay
buffer, and 220ul DMSO. Pipet 20ul into the first two wells of row D in the microplate.
7.
To make 25mM solution, add 50ul of the 500mM stock solution, 750ul of beta lactamase assay
buffer, and 200ul DMSO. Pipet 20ul into the first two wells of row E in the microplate.

8.
To make 50mM solution, add 100ul of the 500mM stock solution, 750ul of beta lactamase assay
buffer, and 150ul DMSO.
9.
Set up Inhibition Reaction Mixes consisting of 48uL of b-Lactamase Assay buffer and 2ul
of b-Lactamase. 50ul of the Inhibition Reaction Mix is required for each well.
10. Add 50ul of the appropriate Inhibition Reaction Mix to each well. Mix well by pipetting.
11. Incubate the plate at 25 °C for 10 minutes. Protect the plate from light during the incubation
12. Set up an Enzymatic Reaction Mix consisting of 29uL b-Lactamase Assay Buffer and 1uL
Nitrocefin. 30uL of the Enzymatic Reaction Mix is required for each well.
13. Add 30 uL of the Enzymatic Reaction Mix to each reaction well. Mix well using a pipette.
14. Measure the absorbance (ABS, A490) in a microplate reader in kinetic mode for 10–30
minutes. Take absorbance readings every minute
15. Using terephthalic acid and b-Lactamase Assay, make a 500mM concentration in order to
make additional concentration strengths to be tested. Add 249.195mg with 3 mL of b-Lactamase
Assay.
16. Repeat steps 2-14
17. Using homophthalic acid and b-Lactamase Assay, make a 500mM concentration in order to
make additional concentration strengths to be tested. Add 180.16mg of homophthalic acid with
3mL of b-Lactamase Assay.
18. Repeat steps 2-14.
19. Using 1,2 Phenylenediacetic acid and b-Lactamase Assay, make a 500mM concentration in
order to make additional concentration strengths to be tested. Add 291.27mg of 1,2
Phenylenediacetic acid with 3mL b-Lactamase Assay.
20. Repeat steps 2-14.
21. Run a blank sample consisting of 50uL and 30uL Enzymatic Reaction Mix to establish a
100% activity level can be established.

Results

Figure 5: Beta-Lactamase activity graphs for terephthalic acid, phthalic acid, and 1,2-phenylene
diacetic acid. The two lines represent the two wells ran for each inhibitor.

Figure 6: The beta-lactamase activity is shown at each concentration level of the three inhibitors
tested. The error bar are individually set to the error for each data point gathered.

The data analyse consisted of graphing the increase in absorbance at 490 nm as a function of
reaction time for each concentration of the inhibitor and getting an average slope for the two
trials. The average slope of activity was then divided by that of activity without an inhibitor to
determine the percent activity for the varying concentrations. The percent activity was then
graphed against common log of the inhibitor concentration. These values were regraphed to
construct the Hill plot to determine the Hill coefficient and at what concentration each molecule
inhibited b-lactamase 50%(IC 50). The Hill plot was constructed by plotting Log (Y/(1-Y)) as a
function of Log X, where Y is the percent activity and X is the molar concentration of the
inhibitor. The Hill coefficient and IC50 were determined from the slope and the x-intercept of the
Hill plot. The best fit curve was obtained using the following equation:

Where Max is the maximum activity, Min is the minimum activity, X is the molar concentration of
the inhibitor, Hill is the Hill coefficient from the Hill plot.

Discussion
The purpose of this study was to determine if phthalic acid, terephthalic acid, and 1,2phenylenediacetic acid could inhibit beta-lactamase activity and then compare them against one
another by finding the IC50 for each inhibitor. In the research study referenced in the intro, it
was inferred that the carboxyl groups of 4-butyl-3-methylphthalic acid were the major factor that
lead it to being an inhibitor [3]. Due to this information, it was predicted that 1,2phenylenediacetic acid would be the best inhibitor due to its large functional groups and their
close placement to one another on the molecule. It was determined that these inhibitors were
not very successful inhibitors of beta-lactamase. The results seem to be confirmed with the
docking simulation. The simulation shows that the inhibitors chosen don’t specifically bond to
the active site, making it a non-successful inhibitor.
The prediction that 1,2-phenylenediacetic acid would be the best inhibitor was not supported by
the data gathered from this experiment. Looking at the graph in Figure 6, it is clear that all of the
molecules inhibited the beta-lactamase activity. The data showed that actually terephthalic acid
was the most inhibitory of beta-lactamase. The IC50 for terephthalic acid was not able to be
determined, however the smallest concentration of terephthalic acid tested,1.5 micromolar,
yielded a b-lactamase activity of 34%, in other words an inhibition rate of 66%. The IC 50 values
found for phthalic acid and 1,2-phenylenediacetic acid was 8.0 +/- 0.6 mM and 2.8 +/- 0.8 mM,

respectively. This shows that 1,2-phenylenediacetic acid was slightly better inhibitor than
phthalic acid. Phthalic acid and 1,2-phenylenediacetic acid are both similar in structure and
inhibition of beta-lactamase. Terephthalic is the most different in structure with its carboxyl
groups spread out the furthest. This could point towards the distance of the carboxyl groups
having a greater impact on inhibition of beta-lactamase. Even though these molecules showed
the ability to inhibit b-lactamase activity, it is unlikely that these molecules would make it to the
clinical level due to the large concentration of each molecule needed to inhibit b-lactamase
activity. Clinical drugs used are in nanomolar concentration while this experiment showed that
micromolar concentrations were necessary for inhibition.
One challenge that arose during this experiment was the limited source of beta-lactamase
buffer. The protocol required a lot of it and only 25mL was able to be purchased due to high
costs. As seen in Fig.4, phthalic acid has more data points than 1,2-phenylenediacetic acid and
terephthalic acid. This was due to phthalic acid being used first to determine what
concentrations would produce 50% inhibition on b-lactamase. Once determining a set of
concentrations that provided a thorough range of inhibition, those concentrations were also
used for terephthalic acid and 1,2-phenylenediacetic acid. Another challenge that arose was
that during the pipetting of the enzyme reaction mix into the wells, air bubbles would form. It was
difficult to get rid of all the air bubbles and they may have impacted the data obtained. The
original protocol also called for the potential inhibitors to be dissolved into beta-lactamase buffer
but due to the insolubility of the inhibitors, DMSO had to be used instead. The activity versus
time graph was also a challenge to deal with due to the graph leveling off fast and being nonlinear. This occured when low concentrations of the inhibitors were used and introduced lare
errors when the activity of beta-lactamase was high.
Conclusion
According to the results gathered from this experiment, phthalic acid, 1,2-phenylenediacetic
acid, and terephthalic acid are all inhibitors or b-lactamase activity. While it was predicted that
1,2-phenylenediacetic acid would have the best inhibition, it was actually terephthalic acid with
the best rate of inhibition. IC 50 values found for phthalic acid and 1,2-phenylenediacetic acid
was 8.0 +/- 0.6 mM and 2.8 +/- 0.8 mM, respectively. respectively. Even though these
molecules showed the ability to inhibit beta-lactamase activity, it is unlikely that these molecules
would make it to the clinical level due to the large amount of each molecule needed to inhibit
beta-lactamase activity. Clinical drugs used are in the concentration of nano molar while this
experiment showed that micro molar concentrations were necessary for inhibition. In the future,
I hope other students continues this research and take a further look into the effect of the
distance of the carboxyl groups has on the inhibition of beta-lactamase activity.
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ABSTRACT

RESULTS

MATERIALS and METHODOLOGY

As a Cell and Molecular major with a Pre-Pharmacy emphasis, medicine has been
an interest of mine. The major cause of increasing bacterial resistance to betalactam antibiotics is due to the expression of the enzyme, beta-lactamase, in
bacteria. This leads to the inactivation of the antibiotics and preventing cell death.
The currently known inhibitors of beta-lactamase are clavulanic acid, sulbactam,
and tazobactam. These are the only inhibitors that have reached clinical
importance. Phthalic acid derivatives have been identified as potential inhibitors.
Phthalic acid, terephthalic acid, and 1,2-phenylenediacetic acid were tested for
beta-lactamase inhibition at various concentrations to determine the IC50 values.
The data showed that terephthalic acid was the most inhibitory of beta-lactamase.
The IC50 for terephthalic acid could not be fully determined, however the lowest
concentration of terephthalic acid tested,1.5 mM, yielded a beta-lactamase activity
of 34%, in other words, an 66% inhibition. The IC50 values for phthalic acid and
1,2-phenylenediacetic acid were 8.0 ± 0.6 mM and 2.8 ± 0.8 mM, respectively.
Phthalic acid and 1,2-phenylenediacetic acid are both similar in structure and
inhibition of beta lactamase. The structure of terephthalic is the most different
with its two carboxyl groups spread out the furthest. This could point towards the
distance of the carboxyl groups having a greater impact on inhibition of betalactamase. Although all three phthalic acid derivatives showed the ability to inhibit
beta-lactamase, it is unlikely that these molecules would make it to the clinical level
due to the high concentration of each molecule needed to inhibit beta-lactamase
activity. Clinical drugs used are in the concentration of nanomolar while this
experiment showed that millimolar concentrations were necessary for inhibition.
In the future, I hope another student continues this research and takes a further
look into the effect of the distance of the carboxyl group has on the inhibition of
beta-lactamase activity. .

Phthalic acid, terephthalic acid, 1,2-phenylenediacetic acid, the Beta-Lactamase
Screening Kit ( MAK222) including beta-lactamase, beta-lactamase assay buffer and
clavulanic acid, and nitrocefin were purchased from Sigma Aldrich. Concentrations
of 500mM of Phthalic acid, terephthalic acid, and 1,2-phenylenediacetic acid were
made using the the drugs and DMSO. From the 500mM concentration,
concentrations of 1.5 mM, 2.5 mM, 5 mM, 25 mM, and 50 mM were made for each
drug. 30 µl of enzymatic reaction mix consisting of 29 µL b-Lactamase Assay Buffer
and 1 µL Nitrocefin was added to 20 µL of each drug. The drug mixtures were
then incubated at 25 °C for 10 minutes. A blank sample without inhibitor was ran
to establish a 100% activity level. Clavulanic acid was also used as a known
inhibitor of beta-lactamase activity. 30 µL enzyme was added to initiate the
reaction. The absorbance at 490 nm was measured using a SpectraMax M5
microplate reader from Molecular Devices in kinetic mode for 10 minutes, taking
the absorbance reading every 30 seconds. The data was then used to see betalactamase activity over time for each concentration to establish an activity curve.

Figure 2: Phthalic
Acid

Figure 3: 1,2Phenylenediacetic Acid

Figure 4: Terephthalic Acid

DISCUSSION

.

Figure 5: Beta-lactamase activity
graphs for phthalic acid, 1,2phenylenediacetic acid, and
terephthalic acid. The two lines
represent the two trials for each
inhibitor.

The data analysis consisted of graphing the increase in absorbance at 490 nm as a function
of reaction time for each concentration of the inhibitor and getting an average slope for
the two trials. The average slope of activity was then divided by that of activity without an
inhibitor to determine the percent activity for the varying concentrations. The percent
activity was then graphed against common log of the inhibitor concentration. These values
were then used to construct the Hill plot to determine the Hill coefficient and the
concentration of each molecule at 50% beta-lactamase activity (IC50). The Hill plot was
constructed by plotting Log (Y/(100-Y)) as a function of Log X, where Y is the percent
activity and X is the molar concentration of the inhibitor.

INTRODUCTION
Beta-lactam antibiotics work by blocking cell wall synthesis of the bacteria and are
a common drug used to treat bacterial infections. A major problem developing
today in the world is the increase in bacteria being resistant to beta-lactam
antibiotics(1,4). The major cause of increasing bacterial resistance to beta-lactam
antibiotics is due to the expression of the enzyme beta-lactamase in bacteria (1,4).
Beta-lactamase is able to hydrolyzes beta-lactam antibiotics in bacteria that contain
the beta-lactamase coding gene(1). This leads to the inactivating of the antibiotics
and preventing cell death. This problem has provided a challenge in finding betalactamase inhibitors so these beta-lactam antibiotics can continue to kill bacterial
infections.
There are a few inhibitors that have been found already for beta-lactamase. The
currently know inhibitors are clavulanic acid, sulbactam, and tazobactam(2). These
are the only three inhibitors that have reached clinical importance(2). However,
some other potential inhibitors of beta-lactamase have been identified, including
phthalic acid derivatives.
A research study performed by Yukiko Hiraiwa, Akihiro Morinaka, Takayoshi
Fukushima, and Toshiaki Kudo has given evidence to this. In their study, they set out
to find metallo-beta-lactamase inhibitory activity of phthalic acid derivatives and
found that the two carboxyl groups of phthalic acid derivative compounds might
interact with zinc in the active site of the enzyme, which could then inhibit the
beta-lactamase produced (3). They then fixed the two carboxyl groups and
investigated the effect of substitution of the phenyl ring on metallo-beta-lactamase
inhibitory activity(3). In the experiment 4-butyl-3-methylphthalic acid was
recognized as a metallo-beta-lactamase inhibitor. The structure–activity
relationship study of substituted phthalic acids afforded 3-phenylphthalic acid
derivatives as potent metallo-beta-lactamase inhibitors(3).

My proposal is to use the beta-lactamase
enzyme activity to find the inhibiting ability
for phthalic acid, 1,2-phenylenediacetic acid,
and terephthalic acid.
Beta-lactamase enzyme activity was assayed
colorimetrically at 490 nm using the Sigma
Aldrich Beta-Lactamase Screening Kit
(MAK222). The activity was measured by
monitoring a colored product by hydrolyzing
the lactam ring of a substrate, nitrocefin. The
structure of nitrocefin is shown below.

Docking simulation of phthalic acid at the
active site of beta-lactamase (1BLC). The
calculated KI was 2.2 mM (8).

The Hill coefficient and IC50 were
determined from the slope and the
antilog of the x-intercept of the Hill plot.
Figure 6: Percent activity versus log
concentration
The best fit curve was obtained using
the following equation:

Docking simulation of Terephthalic acid at
the active site of beta-lactamase
(1BLC). The calculated KI was 2.1 mM (8).

Docking simulation of 1,2Phenylenediacetic acid at the active site
of beta-lactamase (1BLC). The
calculated KI was 1.4 mM (8).

Inhibition of beta-lactamase by clavulanate. Trapped
intermediates in cryo crystallographic studies
(5,6,7).

CONCLUSION

According to the results gathered from this experiment, phthalic acid, 1,2phenylenediacetic acid, and terephthalic acid are all inhibitors or b-lactamase activity.
While it was predicted that 1,2-phenylenediacetic acid would have the best inhibition, it
was actually terephthalic acid with the best rate of inhibition. Even though these
molecules showed the ability to inhibit beta-lactamase activity, it is unlikely that these
molecules would make it to the clinical level due to the large amount of each molecule
needed to inhibit beta-lactamase activity. Clinical drugs used are in the concentration of
nanomolar while this experiment showed that millimolar concentrations were necessary
for inhibition. In the future, I hope other students continues this research and take a
further look into the effect of the distance of the carboxyl groups has on the inhibition of
beta-lactamase activity.
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where Max is the maximum activity, Min is the minimum activity, X is the molar
concentration of the inhibitor, and Hill is the Hill coefficient from the Hill plot. The percent
beta-lactamase activity is shown at each concentration level of the three inhibitors tested.
The error bar are individually set to the error for each data point gathered.
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